Partnering with JCR
Together We Soar.
JCR is pleased to highlight our clinical achievements with four oral presentations and 10 posters at WORLDSymposium™ 2023.
Download an overview of our WORLDSymposium™ 2023 abstracts Learn More About WORLDSymposium™
We will continuously try to create value by our unique technology platform such as J-Brain Cargo® toward our corporate philosophy: “contributing towards people’s healthcare through pharmaceutical products.”
In addition to the in-house research activities, we think collaborative research and development work with other companies are also important. The values of our technology platform will be increased by integrating our technologies and other technologies and by implementing our technology in other companies’ products. We aim at “research-oriented specialty pharma with global exposure” utilizing collaborative research and development work.

JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. Our core values – reliability, confidence, and belief – means that the work we do benefits all our stakeholders, including employees, partners, and patients.
We continue to build upon our 48-year legacy in Japan while expanding our global footprint with trials in the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. If you are interested in speaking with JCR regarding business development opportunities, email bd@jcrpharm.co.jp.
Patient Commitment
We Stand with Patients
At JCR, we are united with the patients, families, and communities we serve. We seek to understand their needs and develop new medicines with significant and meaningful benefits. We created JCR to improve the lives of people with rare and genetic diseases, and we remain driven by this common purpose.
We recognize the limitations of available therapies for rare and genetic diseases, including lysosomal storage disorders such as MPS Type I, MPS Type II, and MPS Type III. Many people with these conditions experience severe complications of the central nervous system (CNS). Developmental delays, impaired cognition, and an overall poor prognosis can negatively impact independence and quality of life for both patients and caregivers.
Together, we are working towards better outcomes for patients.


Global Expansion
We continue to build upon our history of success in Japan while expanding our global footprint by developing first-in-class and best-in-class therapies, and further expanding our capabilities in manufacturing and R&D.
Recent News Milestones
September 2020 |
|
---|---|
October 2020 |
|
December 2020 |
|
February 2021 |
|
March 2021 |
|
May 2021 |
|
September 2021 |
|
October 2021 |
|
January 2022 |
|
February 2022 |
|
March 2022 |
|
July 2022 |
|
September 2022 |
|
October 2022 |
|
January 2023 |
|
March 2023 |
|
May 2023 |
|
July 2023 |
|
View our WORLDSymposium™ 2023 Abstracts

This year, JCR Pharmaceuticals attended the virtual 19th annual WORLDSymposium™, an annual conference dedicated to lysosomal storage disorders, Feb. 22-26. We had four oral presentations and 10 posters at the event.
Development Pipeline – October 2023
Target Indicators | Basic Research | Animal Model Study |
Process Development* Including development of industrial scale process, testing method and formulation | Preclinical | Clinical | Application for marketing approval |
Approved/Launch |
---|---|---|---|---|---|---|---|
Target Indicator: MPS II - Hunter** JR-141 (Japan) Development Stage: Approved/Launch |
JR-141 (Japan) |
||||||
Target Indicator: MPS II - Hunter JR-141 (U.S., EU, and Latin America) Development Stage: Clinical (Global) |
JR-141 (US, Europe, Asia, and Latin America) |
||||||
Target Indicator: MPS I - Hurler etc. JR-171 Development Stage: Clinical (Global) |
JR-171 |
||||||
Target Indicator: Pompe disease JR-162 Development Stage: Preclinical |
JR-162 |
||||||
Target Indicator: MPS IIIA - Sanfilippo A JR-441 Development Stage: Preclinical |
JR-441 |
||||||
Target Indicator: MPS IIB - Sanfilippo B JR-446 Development Stage: Preclinical |
JR-446 |
||||||
Target Indicator: MPS VII - Sly JR-443 Development Stage: Preclinical |
JR-443 |
||||||
Target Indicator: GM2 gangliosidosis - Tay‑Sachs disease Development Stage: Process Development* Including development of industrial scale process, testing method and formulation |
JR-479 |
||||||
Target Indicator: Fucosidosis Development Stage: Process Development* Including development of industrial scale process, testing method and formulation |
JR-471 |
||||||
Target Indicator: Krabbe disease Development Stage: Process Development* Including development of industrial scale process, testing method and formulation |
|||||||
Target Indicator: CLN1 - Batten disease infantile Development Stage: Animal Model Study |
JR-194 |
||||||
Target Indicator: GM1 gangliosidosis Development Stage: Animal Model Study |
|||||||
Target Indicator: Metachromatic leukodustrophy Development Stage: Animal Model Study |
|||||||
Target Indicator: CLN2 - Batten disease late infantile Development Stage: Process Development* Including development of industrial scale process, testing method and formulation |
|||||||
Target Indicator: Gaucher disease Development Stage: Animal Model Study |
|||||||
Target Indicator: Niemann-Pick disease Development Stage: Animal Model Study |
|||||||
Target Indicator: ɑ-Mannosidosis Development Stage: Animal Model Study |
|||||||
Target Indicator: Galactosialidosis Development Stage: Basic Research |
*Including development of industrial scale process, testing method and formulation
**Approved in Japan march 2021 and launched in May 2021
J-Brain Cargo® Technology

Our first-in-class proprietary technology, J-Brain Cargo®, enables us to develop therapies that cross the blood-brain barrier and penetrate the central nervous system (CNS). The CNS complications of diseases are often severe, resulting in developmental delays, an impact on cognition and, above all, poor prognosis, which affect patients’ independence as well as the quality of life of patients and their caregivers. With J-Brain Cargo®, we seek to address the unresolved clinical challenges of lysosomal storage disorders by delivering the enzyme to both the body and the brain.
Contact
If you are interested in speaking with JCR regarding business development opportunities, email bd@jcrpharm.co.jp.